![pomona](http://www.pomonaricerca.com/wp-content/plugins/revslider/public/assets/assets/dummy.png)
Who we are
We are a private Italian
R&D biotech company
Every breakthrough at Pomona Ricerca is driven by our commitment to improving patient outcomes. We strive to enhance the quality of life for individuals by delivering effective and safe immunotherapeutic solutions. At the heart of Pomona Ricerca's vision lies a fervent dedication to advancing research in monoclonal antibodies to prevention and treatment of infectious diseases.
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/pomona-ricerca-8.jpg)
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/pomona-ricerca-11.jpg)
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/pomona-ricerca-13.jpg)
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/pomona-ricerca-12.jpg)
POMONA RICERCA
Our strategy
Pomona Ricerca provides indispensable services in the critical pre-clinical characterization stage of drug development.
The business model of Pomona Ricerca operates on three fronts:
- designing and developing new monoclonal antibodies, followed by out-licensing the mAbs at the pre-clinical characterization stage
- developing of antibody-based vaccines
- providing proteins and services for the characterization of new monoclonal antibodies
Our comprehensive approach, blending consolidated scientific expertise with cutting-edge technologies, positions us as an attractive partner for biotech firms, pharmaceutical companies, and research institutions aiming to bring novel therapeutics to market.
Pomona ricerca
Products & Services
Pomona ricerca
News
Enhancing anti-HIV vaccine development: the immunogenic potential of the Minibody format
Advancements in medical research have not yet yielded an effective vaccine against different pathogens, with HIV
Advancing toward an HIV-free future: the imperative of vaccine development
The adage ‘An ounce of prevention is worth a pound of cure’ rings true, especially in the context of
Avian Influenza virus infections in human
The CDC recently reported four human infections with the highly pathogenic avian influenza (HPAI) A (H5N1) virus
Pomona ricerca
Partnership
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/partner-polymun.png)
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/partner-biomed.png)
![Pomona Ricerca](https://www.pomonaricerca.com/wp-content/uploads/2024/02/partner-genertech-2.png)